Hossein Khadem Haghighian1, Fatemeh Haidari2, Javad Mohammadi-Asl3, Mohammadreza Dadfar4. 1. Department of Nutrition, School of Paramedical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 2. Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Electronic address: haidari58@gmail.com. 3. Department of Medical Genetics, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 4. Department of Urology, Imam Khomeini Hospital, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Abstract
OBJECTIVE: To evaluate effects of supplementation with alpha-lipoic acid (ALA) on the spermatogram and seminal oxidative stress biomarkers. DESIGN: Randomized, triple-blind, placebo-controlled clinical trial. SETTING: Infertility clinic. PATIENT(S): Infertile men. INTERVENTION(S): ALA (600 mg) or placebo for 12 weeks. MAIN OUTCOME MEASURE(S): Semen analysis, anthropometric, dietary, and physical activity assessments, total antioxidant capacity, and malondialdehyde. RESULT(S): At the end of study, the total sperm count, sperm concentration, and motility in the intervention group were significantly higher than in the control group. In the ALA group, the total sperm count, sperm concentration, and motility levels were also significantly increased at the end of study compared with baseline values. However, there were no significant differences in ejaculate volume, normal morphology percentage, and live sperm between groups. ALA supplementation also resulted in a significant improvement in seminal levels of total antioxidant capacity (TAC) and malondialdehyde compared with the placebo. CONCLUSION(S): According to the results, medical therapy of asthenoteratospermia with ALA supplement could improve quality of semen parameters. However, further investigation is suggested in this regard. CLINICAL TRIAL REGISTRATION NUMBER: IRCT2013111010181N3.
RCT Entities:
OBJECTIVE: To evaluate effects of supplementation with alpha-lipoic acid (ALA) on the spermatogram and seminal oxidative stress biomarkers. DESIGN: Randomized, triple-blind, placebo-controlled clinical trial. SETTING: Infertility clinic. PATIENT(S): Infertile men. INTERVENTION(S): ALA (600 mg) or placebo for 12 weeks. MAIN OUTCOME MEASURE(S): Semen analysis, anthropometric, dietary, and physical activity assessments, total antioxidant capacity, and malondialdehyde. RESULT(S): At the end of study, the total sperm count, sperm concentration, and motility in the intervention group were significantly higher than in the control group. In the ALA group, the total sperm count, sperm concentration, and motility levels were also significantly increased at the end of study compared with baseline values. However, there were no significant differences in ejaculate volume, normal morphology percentage, and live sperm between groups. ALA supplementation also resulted in a significant improvement in seminal levels of total antioxidant capacity (TAC) and malondialdehyde compared with the placebo. CONCLUSION(S): According to the results, medical therapy of asthenoteratospermia with ALA supplement could improve quality of semen parameters. However, further investigation is suggested in this regard. CLINICAL TRIAL REGISTRATION NUMBER: IRCT2013111010181N3.
Authors: Wiep de Ligny; Roos M Smits; Rebecca Mackenzie-Proctor; Vanessa Jordan; Kathrin Fleischer; Jan Peter de Bruin; Marian G Showell Journal: Cochrane Database Syst Rev Date: 2022-05-04
Authors: Roos M Smits; Rebecca Mackenzie-Proctor; Anusch Yazdani; Marcin T Stankiewicz; Vanessa Jordan; Marian G Showell Journal: Cochrane Database Syst Rev Date: 2019-03-14
Authors: Fabiana A de Oliveira; Waldemar S Costa; Francisco J B Sampaio; Bianca M Gregorio Journal: Asian J Androl Date: 2019 Mar-Apr Impact factor: 3.285
Authors: Andrea Garolla; Gabriel Cosmin Petre; Francesco Francini-Pesenti; Luca De Toni; Amerigo Vitagliano; Andrea Di Nisio; Carlo Foresta Journal: Nutrients Date: 2020-05-19 Impact factor: 5.717